JPRN-UMIN000012293已完成2 期
eoadjuvant radiation therapy concurrent with S-1 followed by systemic Gemcitabine therapy for Borderline resectable pancreatic cancer patients; A phase2 study - A phase2 study of neoadjuvant S1+RT followed by systemic Gem therapy for Borderline resectable pancreatic cancer patients
Hokkaido Pancreatic Cancer Study Group (HOPS)0 个研究点目标入组 45 人开始时间: 2013年11月15日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 45
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 75years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) treatment history of a pancreatic cancer (chemotherapy, radiotherapy, surgical) 2) treatment history of other malignant tumors (chemotherapy, radiotherapy) 3) Patients who can' t receive neither iodic drug because of drug allergy 4) Including in an exposure field is impossible with contrast enhanced CT 5) Massive pleural or abdominal effusion 6) Pleural membranes and peritoneum sowing are proved by cytological diagnosis 7) Existence of tumor exposure with CT or Endoscope 8) Hemorrhagic peptic ulcer 9) Watery diarrhea 10) Regular use of frucitocin, fenitoin or warfarin 11) Lung fibrosis or intestinal pneumonia, and anamnesis or imaging findings 12) Severe infection 13) Serious complications (e.g. heart failure, hepatic failure, intestinal paralysis, intestinal obstruction) 14) Uncontrolled diabetes 15) Simultaneous or metachronous (within 3 years) double cancers 16) Patients requiring systemic steroids medication 17) Severe mental illness 18) Severe drug hypersensitivity 19) Males that are currently attempting to produce a pregnancy 20) Pregnant females, possibly pregnant females, females wishing to become pregnant 21) Patients seems inadequate for this study by investigators
研究者
相似试验
已完成
不适用
eoadjuvant radiation therapy concurrent with S-1 followed by systemic S-1/Gemcitabine therapy for Borderline resectable pancreatic cancer patients; A pilot studypancreatic cancerJPRN-UMIN000008888Department of Surgical Oncology and Gastroenterological Surgery, Sapporo Medical University Hospital30
进行中（未招募）
不适用
Radiation therapy and concurrent plus adjuvant Temsirolimus (CCI-779) versus chemo-irradiation with Temozolomide in newly diagnosed glioblastoma without methylation of the MGMT gene promoter – a randomized multicenter, open-label, Phase II studypatients with newly diagnosed glioblastoma (GBM) without methylation of the DNA-repair enzyme O6-methylguanin-DNA-methyltransferase (MGMT) gene promoterMedDRA version: 9.1Level: LLTClassification code 10006153Term: Brain tumorEUCTR2008-003003-31-NLEORTC Headquarters108
进行中（未招募）
不适用
Radiation therapy and concurrent plus adjuvant Temsirolimus (CCI-779) versus chemo-irradiation with Temozolomide in newly diagnosed glioblastoma without methylation of the MGMT gene promoter – a randomized multicenter, open-label, Phase II studypatients with newly diagnosed glioblastoma (GBM) without methylation of the DNA-repair enzyme O6-methylguanin-DNA-methyltransferase (MGMT) gene promoterMedDRA version: 9.1Level: LLTClassification code 10006153Term: Brain tumorEUCTR2008-003003-31-ATEORTC Headquarters108
进行中（未招募）
不适用
Radiation therapy and concurrent plus adjuvant Temsirolimus (CCI-779) versus chemo-irradiation with Temozolomide in newly diagnosed glioblastoma without methylation of the MGMT gene promoter a randomized multicenter, open-label, Phase II study. - NDpatients with newly diagnosed glioblastoma without methylation of the MGMT gene promotorMedDRA version: 12.0Level: LLTClassification code 10018336Term: GlioblastomaEUCTR2008-003003-31-ITE.O.R.T.C. - EUROPEAN ORGANIZATION FOR RESEARCH AND TREATMENT OF CANCER108
进行中（未招募）
不适用
Radiation therapy and concurrent plus adjuvant Temsirolimus (CCI-779) versus chemo-irradiation with Temozolomide in newly diagnosed glioblastoma without methylation of the MGMT gene promoter – a randomized multicenter, open-label, Phase II studypatients with newly diagnosed glioblastoma (GBM) without methylation of the DNA-repair enzyme O6-methylguanin-DNA-methyltransferase (MGMT) gene promoterMedDRA version: 13.1Level: LLTClassification code 10006153Term: Brain tumorSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2008-003003-31-DEEORTC Headquarters108